Videos

Graft versus Host Disease

A 61-Year-Old Man With ALK-Rearranged NSCLC

Daniel P. Petrylak, MD, discusses the data from the phase II EV-201 trial investigating enfortumab vedotin as treatment of patients with locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy or a PD-1/PD-L1 checkpoint inhibitor.

David Bond, MD, discusses 2 key findings from a recent study investigating the risk of developing a second cancer in patients with chronic lymphocytic leukemia treated with a BTK inhibitor.

Ryan Weight, DO discusses takeaways from the Immuno-Oncology Institute Working Group Summit. The summit was a part of the Association of Community Cancer Centers’ Immuno-Oncology Institute and brought together multidisciplinary working groups to strategize policy and delivery changes for the effective use of immunotherapy.

Karim Fizazi, MD, PhD, discusses the potential role for darolutamide in combination with androgen deprivation therapy in patients with nonmetastatic castration-resistant prostate cancer.

Richard T. Penson, MD, discusses the toxicities that were demonstrated in the long-term follow-up of the phase III SOLO3 trial. This multicenter, open-label trial investigated single-agent olaparib in patients with platinum-sensitive, relapsed, BRCA-mutated ovarian cancer who have received at least 2 prior lines of chemotherapy.

Howard S. Hochster, MD, discusses the role of TAS-102 in patients with gastric/gastroesophageal junction or colorectal cancer in comparison to fluorouracil.

Fred R. Hirsch, MD, PhD, shares a message with oncologists regarding molecular testing in patients with lung cancer. He says the most important message is that molecular characterization of the patient’s tumor must be done in order to best treat the patient.

Peter Voorhees, MD, discusses the latest data for the use of pomalidomide-containing regimens for the treatment of patients with relapsed/refractory multiple myeloma. He highlights data from 2 randomized clinical trials that demonstrated an improvement in responses with pomalidomide-based triplets.

Heather A. Wakelee, MD, discusses recent research investigating antiangiogenic agents and checkpoint inhibitors in the frontline for patients with <em>EGFR</em>-positive non&mdash;small cell lung cancer. The most promising data were demonstrated in the phase III IMpower150 trial.

The research around best radiation-based treatment options for patients with hepatocellular carcinoma are over 15 years old, but the standard of care for long-term management of the disease is still conventional chemoembolization, according to Emil I. Cohen, MD, assistant professor, Georgetown University Hospital.

Patients with relapsed or refractory acute myeloid leukemia typically have low response rates to chemotherapy. However, some subsets of patients, particularly those with targetable mutations, may have long-term survival when given a novel FLT3 inhibitor like gilteritinib, as seen in the ADMIRAL trial, says Mark J. Levis, MD, PhD.

Pashtoon M. Kasi, MBBS, MD, MS, clinical assistant professor of internal medicine, University of Iowa Carver College of Medicine, discusses how serial testing via liquid biopsies in patients with gastrointestinal cancers can provide oncologists with a better picture of the patient&rsquo;s condition and potential acquired mechanisms of resistance.

Ravi Salgia, MD, professor and chair, Department of Medical Oncology &amp; Therapeutics Research, associate director for clinical sciences, City of Hope, Durante, California, says there is a difference between precision medicine and personalized medicine.

Michael J. Mauro, MD, discusses how 4 FDA-approved frontline therapies are providing benefit to patients with chronic myeloid leukemia

Sara M. Tolaney, MD, MPH, discusses the evolving role of neoadjuvant endocrine therapy in the breast cancer space. She says there is particular interest in using this therapy in patients with HER2-positive and triple-negative breast cancer, but it can be more challenging in patients with ER-positive disease.

Marina Kremyanskaya, MD, PhD, discusses unique findings from the phase II trial investigating the effect of CPI-0610, a bromodomain and extra-terminal protein inhibitor, as treatment for patients with myelofibrosis who previously progressed on ruxolitinib.